On the basis of geography, theglobal HumanChorionic Gonadotropin Market is segmented into North America, LatinAmerica, Europe, Asia Pacific, Middle East, and Africa. North America is thehighest regional contributor to the market and is expected to continue as aregional dominator over the forecast years. This primarily owes to the risingnumber of infertility cases as well as hormonal dysfunction among young malesand females as a result of changing lifestyle. According to Mayo Clinic, around25% of women fertility problems in the U.S. are a result of ovulation issuesthat are mostly caused due to dysfunction of human chorionic gonadotropin (HCG)hormone. Thus, the rapidly increasing cases of infertility are expected tosurge the North America global human chorionic gonadotropin market. On the otherhand, Asia Pacific is anticipated to be the fasting growing geography, owing toeconomic developments facilitating technological advancements in healthcaresectors as well as emerging local players in the market.
Human chorionic gonadotropinhormone (HCG) is a hormone secreted by the placenta after implantation of afertilized zygote in the uterus. The hormone also supports normal developmentof an egg and helps in the stimulation of egg release from the ovary. The HCGis mainly used to induce ovulation in the women under infertility treatment. Itis also used among males mostly to increase the sperm count and in young boys,due to pituitary gland disorders and other diseases, due to which the testiclesof the young males does not drop down naturally into the scrotum. The HCG isusually administered as an injection under the skin into a muscle. The HCG canalso be administered at home under the advice of a gynecologist or apharmacist.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/1011
The HCG levels can be determinedwith the help of urine or blood test. Result of specific test helps in thedetermining accurate measurement of the levels. These tests are mostly used toidentify and confirm pregnancy or as a screening test to determine birthdefects.
Rising incidence of infertilityare expected to drive the growth of human chorionic gonadotropin market acrossthe globe
According to Centers of DiseaseControl and Prevention (CDC) in 2016, approximately 7.3 million women aged 15 -44 have used infertility services. Moreover, 6.7% of the married women aged 15- 44 were reported infertile. According to Azura Vascular Care, around 17% ofthe couples in the U.S. deal with infertility out of which 30% cases are aresult of male infertility. These numbers suggests significant demand forinfertility treatments, such as HCG in order for females to conceive a child.According to a statistical survey conducted by HealthGrove, pituitary glanddisorders resulted into the death of around 205 people in 2015, out of whichhighest percentage belonged to white men. Pituitary disorders resulting intosignificant mortality rate are propelling the demand for human chorionicgonadotropin hormone. Additionally, various other factors such asendometriosis, hormonal imbalance, polycystic ovary syndrome, and others areexpected to propel the growth of global HCG market.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/human-chorionic-gonadotropin-market-1011
For instance, according to FriscoInstitute of Reproductive Medicine, around 10% of women of reproductive age inthe U.S. suffer from polycystic ovary syndrome. However, easy availability ofalternatives to treat infertility could act as potential barriers for themarket growth.
North America to dominate globalhuman chorionic gonadotropin (HCG) market, owing to rising frequency ofinfertility cases
The key players operating theglobal human chorionic gonadotropin market include Merck & Co., Inc., EMDSereno, Inc., Fresenius Kabi, Bristol Myers Squibb Company, Ferring BV, andKamia Biomedical Company. Acris Antibodies developed a human chorionic gonadotropinhormone by recombinant DNA technology that helps to prevent the disintegrationof the corpus luteum of the ovary thereby, maintaining levels of progesteroneproduction for healthy pregnancy in females.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/1011
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN: +050-5539-1737
